A review on potential of PARP inhibitors in the treatment of prostate cancer

A review on potential of PARP inhibitors in the treatment of prostate cancer

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2022.

Bibliografski detalji
Glavni autor:	Islam, Saidul
Daljnji autori:	Sharmin, Shahana
Format:	Disertacija
Jezik:	English
Izdano:	Brac University 2022
Teme:	Prostate cancer Therapeutic approaches mCRPC PARP inhibitors Olaparib Cancer > Treatment Enzyme inhibitors > Therapeutic use Cancer > Gene therapy
Online pristup:	http://hdl.handle.net/10361/17308

Similar Items

A review on newly approved PARP inhibitors: Talazoparib and Olaparib
od: Karim, Azrin
Izdano: (2024)

Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
od: Flora, Sanzida Alam
Izdano: (2024)

SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
od: Meem, Manila
Izdano: (2023)

Benign Prostatic Hyperplasia & Prostate Cancer: a review on the treatment strategies
od: Alam, Tahera
Izdano: (2024)

RIPK pathway, as a potential target, for cancer treatment - a review
od: Jahan, Nusrat
Izdano: (2024)

Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
od: Ahmed, Nafisa
Izdano: (2023)

Immunotherapy in the Management of Lung Cancer
od: Tasnim, Humayra
Izdano: (2022)

A review on triple-negative breast cancer and its potential treatment
od: Niasa, Jannatul Ferdous
Izdano: (2023)

Stem cells as therapeutic carrier in cancer treatment
od: Anika, Mysha Yeasmin
Izdano: (2022)

An examination of therapeutic synergy: a comprehensive meta-analysis comparing the efficacy of TAS-102 and FOLFOX as a combination therapy for colon cancer
od: Hasan, Amit
Izdano: (2024)

Drug repurposing: potential of Antimicrobial Drugs in Breast Cancer Treatment
od: Chakraborty, Anuradha
Izdano: (2024)

A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
od: Khan, Muidul Hasan
Izdano: (2024)

A review on potential role of cannabinoids as therapeutic agents in different types of cancer
od: Roy, Hredita
Izdano: (2018)

Recent advances in Cancer treatment targeting autophagy and future aspects
od: Emon, Kamrul Hasan
Izdano: (2022)

Tamoxifen: The ideal post operative hormonal therapy to demote Ductal Carcinoma in Situ
od: Mirza, Maisa Tasnim
Izdano: (2023)

Role of toll-like receptors in cancer immunotherapy– a review
od: Khan, Rezia Nowrin
Izdano: (2021)

In silico analysis revealed hsa-miR-19a-3p and hsa-miR-19b-3p as two potential inhibitors of EGF mRNA in Breast Cancer
od: Nuha, Nabiha Tahsin
Izdano: (2024)

Role of statins as antagonists of SPARC in gastric cancer
od: Shahmat, Rad
Izdano: (2019)

A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
od: Sorno, Rubina Haque
Izdano: (2024)

A review of next-generation immuno-oncology agents for cancer therapy: recent dictation shifts in cancer immunotherapy
od: Ratu, Tabassum
Izdano: (2024)

A review on bispecific antibody (blinatumomab) for the treatment of acute lymphoblastic leukemia
od: Choki, Kinley
Izdano: (2024)

Recent developments in the Adeno-Associated Viral Gene Therapy for Non-Small Cell Lung Cancer during the past 20 years
od: Razna, Amrin Islam
Izdano: (2019)

A comprehensive review on drug repurposing in cancer treatment
od: Sarkar, Onusree
Izdano: (2024)

A review on RNAi technology and its therapeutic potential in Cancer
od: Mahaleka, Aarshi
Izdano: (2024)

Prevalence and application of an evolving genome editing tool “CRISPR/Cas System” in cancer research and treatment
od: Shaikat, Mahdi Mubin
Izdano: (2023)

Genetic innovations for breast cancer treatment : a review of gene therapy strategies and future implications
od: Hasan, Sakib
Izdano: (2024)

Survey on patients undergoing treatments for cervical, endometrial and ovarian cancer
od: Nawar, Anika
Izdano: (2019)

Statistics and informatics in molecular cancer research

Identification of FAP inhibitors using in silico simulation study
od: Deeba, Maliha Tasnim
Izdano: (2018)

Targeting BRAFV600E in the treatment of CRC
od: Roja, Mashwiyat Samrin
Izdano: (2024)

Targeted therapeutic options in the treatment of Breast Cancer
od: Alam, Kazi Tasnuva
Izdano: (2022)

Clinical outcomes and safety comparison of gemcitabine plus cisplatin, capecitabine monotherapy, and gemcitabine plus oxaliplatin in the management of gallbladder carcinoma: a comprehensive meta-analysis
od: Rahman, Sanjida
Izdano: (2024)

Biosimilar in lymphoma treatment
od: Tanisha, Mehrin Haque
Izdano: (2021)

Current practice and approaches of immunotherapy in Cancer treatment
od: Khondokar, Faiza
Izdano: (2022)

A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
od: Islam, Nahidul
Izdano: (2023)

A review on Single Nucleotide Polymorphism (SNPs) and their effect on cancer risk in South Asian population
od: Beruni, Sajid Mahmud Al
Izdano: (2022)

Oncogenes: new targets in cancer treatment
od: Chowdhury, Waseka Shams
Izdano: (2020)

Potential phytochemicals and dietary components for the prevention and treatment of skin cancer: A review
od: Muntaha, Habibatul
Izdano: (2023)

A review of comparison on efficacy, safety and cost effectiveness of cholinesterase inhibitors, NMDA antagonists and combination therapy in the treatment of Alzheimer’s disease
od: Haque, Mushfiqul
Izdano: (2019)

Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
od: Karim, Samia Binte
Izdano: (2024)